When you create Fresh Tracks, you purposefully look to explore beyond. Beyond the expected. Beyond the obvious. Beyond the conventional.
Our company was built from this belief and, in turn, strives to identify, pursue, and develop next-generation, prescription therapeutics that will be groundbreaking in their ability to help millions of people struggling within the devastated communities of autoimmunity, inflammation and other debilitating diseases. Bolstered by seasoned leadership and exceptionally driven talent, we are resolute in our vision.. to explore beyond and accomplish something truly extraordinary.
Together, the executive management team and board of directors combines extensive leadership experience across early-stage research, product development, and global commercialization. Our leadership has served in roles at large global pharmaceutical companies and biotechs that have successfully developed and/or launched first-in-class products that reach iconic status, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide.
We align this expert knowledge with a clear strategy. Our pipeline links several development-stage candidates and a cutting-edge platform with large, high impact potential across autoimmune and inflammatory disorders.